Special Treatment Populations: HIV-Positive Patients

Avants SK, Margolin A, DePhilippis D, and Kosten TR. A comprehensive pharmacologic-psychosocial treatment program for HIV-seropositive cocaine- and opioid-dependent patients: Preliminary findings. Journal of Substance Abuse Treatment (15):261–265, 1998.

Iribarne C, Berthou F, Carlhant D, Dreano Y, Picart D, Lohezic F, and Riche C. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metabolism and Disposition: The Biological Fate of Chemicals (26):257–260, 1998.

Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J, and the Manif 2000 study group. Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment. AIDS (14):151–155, 2000.

Montoya ID, Umbricht A, and Preston KL. Buprenorphine for human immunovirus-positive opiate-dependent patients. Biological Psychiatry (38):131–136, 1995.